Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Zoetis
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.
In the 1950s, Pfizer began research on several drugs, including oxytetracycline, which was found to be effective in livestock. In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo. By 1988 the division was renamed Pfizer Animal Health.
The 1995 acquisition of Norden Laboratories from GlaxoSmithKline expanded Pfizer's animal health division into small animal care, including domestic pets. Secondary research and development centres were opened in Kalamazoo, Michigan, in 2003. In the same year, Pfizer acquired Pharmacia Corporation for US$60 billion in stock options. Between 2007 and 2011, the company acquired Embrex Inc, Catapult Genetics, Bovigen, Wyeth, Fort Dodge Animal Health, Vetnex Animal Health Ltd, Synbiotics Corporation, Microtek, King Pharmaceuticals, and Alpharma.
Plans to break away Pfizer Animal Health into a separate company were officially announced in 2012. The new firm was named Zoetis in allusion to the Greek-derived zoological term zoetic, meaning "pertaining to life".
Zoetis Inc.'s revenues exceeded $4.2 billion in 2011 and $4.34 billion in 2012. The animal health industry worldwide is an estimated US$22 billion industry.
On May 22, 2013, The Wall Street Journal reported that Pfizer planned to sell its majority stake in the company. According to the report, shareholders would have the option to swap their Pfizer shares for Zoetis shares. The sell-off of Zoetis was consistent with Pfizer's recent decision to shed other non-pharmaceutical subsidiaries in an effort to save costs, raise capital, and pay off debt. The company announced that JPMorgan Chase, Bank of America, Merrill Lynch, Goldman Sachs & Co., and Morgan Stanley would be the lead underwriters.
In November 2014, activist investor Bill Ackman disclosed that Pershing Square Capital Management had taken an 8.5% stake in the company, amassing approximately 41.8 million shares, causing the share price to hit its highest price since the IPO. On 17 November, the company announced it would acquire a portfolio of pet drugs from Abbott Laboratories for approximately $255 million.
August 2025, Soros Capital Management bought shares in the company.
Hub AI
Zoetis AI simulator
(@Zoetis_simulator)
Zoetis
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.
In the 1950s, Pfizer began research on several drugs, including oxytetracycline, which was found to be effective in livestock. In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo. By 1988 the division was renamed Pfizer Animal Health.
The 1995 acquisition of Norden Laboratories from GlaxoSmithKline expanded Pfizer's animal health division into small animal care, including domestic pets. Secondary research and development centres were opened in Kalamazoo, Michigan, in 2003. In the same year, Pfizer acquired Pharmacia Corporation for US$60 billion in stock options. Between 2007 and 2011, the company acquired Embrex Inc, Catapult Genetics, Bovigen, Wyeth, Fort Dodge Animal Health, Vetnex Animal Health Ltd, Synbiotics Corporation, Microtek, King Pharmaceuticals, and Alpharma.
Plans to break away Pfizer Animal Health into a separate company were officially announced in 2012. The new firm was named Zoetis in allusion to the Greek-derived zoological term zoetic, meaning "pertaining to life".
Zoetis Inc.'s revenues exceeded $4.2 billion in 2011 and $4.34 billion in 2012. The animal health industry worldwide is an estimated US$22 billion industry.
On May 22, 2013, The Wall Street Journal reported that Pfizer planned to sell its majority stake in the company. According to the report, shareholders would have the option to swap their Pfizer shares for Zoetis shares. The sell-off of Zoetis was consistent with Pfizer's recent decision to shed other non-pharmaceutical subsidiaries in an effort to save costs, raise capital, and pay off debt. The company announced that JPMorgan Chase, Bank of America, Merrill Lynch, Goldman Sachs & Co., and Morgan Stanley would be the lead underwriters.
In November 2014, activist investor Bill Ackman disclosed that Pershing Square Capital Management had taken an 8.5% stake in the company, amassing approximately 41.8 million shares, causing the share price to hit its highest price since the IPO. On 17 November, the company announced it would acquire a portfolio of pet drugs from Abbott Laboratories for approximately $255 million.
August 2025, Soros Capital Management bought shares in the company.